drugset / Trial / NCT02641236

Gut Decontamination In Pediatric Allogeneic Hematopoietic

NCT02641236

Phase 2 Completed 24 enrolled Dana-Farber Cancer Institute
RandomizedParallel-groupOpen-labelPrevention

Summary

This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD). GVHD is a complication of HSCT in which immune cells from the donor cause inflammation and injury to tissues and organs of the HSCT recipient. Vancomycin-polymyxin B (commonly called "vancopoly") is an oral antibiotic that is given to people undergoing allogeneic HSCT as a preventive measure for acute GVHD. This research study is studying the effects of vancopoly on the microorganisms living in the intestine during and after stem cell transplantation.

Timeline

Start
2016-03
Primary completion
2021-04-15
Completion
2021-10-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Polymyxin B Peptide Oral
Comparator Vancomycin Other / unclassified Oral